Investments in Switzerland as a production location – an important signal

The inauguration of Japanese drug major Takeda's (TYO: 4502) new, state-of-the-art filling line at its Neuchâtel, Switzerland, production site sends a powerful message, according to Dr René Buholzer, managing director of Swiss trade group InterPharma.

With an investment of over 200 million Swiss francs ($158 million) – the largest in the site's history – Takeda is clearly demonstrating its commitment to Switzerland as a center for cutting-edge biopharmaceutical research and production. This expansion not only strengthens local value creation but also the global supply of therapies for rare diseases to patients. It exemplifies the high innovative potential, expertise, and reliability of the local research and industrial ecosystem.